HCID 70113844, compound → HCID 178525229, compound
Reaction equation
[C:1]1([C:37]2[CH:42]=[CH:41][CH:40]=[CH:39][CH:38]=2)[CH:6]=[CH:5][C:4]([CH2:7][C@H:8]([NH:18][C:19]([C:21]2([CH2:26][C:27]([O:29]CC3C=CC=CC=3)=[O:28])[CH2:25][CH2:24][CH2:23][CH2:22]2)=[O:20])[C:9]2[N:13](CCC#N)[N:12]=[N:11][N:10]=2)=[CH:3][CH:2]=1>CO.[Pd]>[C:1]1([C:37]2[CH:38]=[CH:39][CH:40]=[CH:41][CH:42]=2)[CH:2]=[CH:3][C:4]([CH2:7][C@H:8]([NH:18][C:19]([C:21]2([CH2:26][C:27]([OH:29])=[O:28])[CH2:25][CH2:24][CH2:23][CH2:22]2)=[O:20])[C:9]2[NH:13][N:12]=[N:11][N:10]=2)=[CH:5][CH:6]=1Participants
Reactant 1
Product 1
Reagents, catalysts & solvents 2
Procedure
(S)-benzyl 2-(1-(2-(biphenyl-4-yl)-1-(1-(2-cyanoethyl)-1H-tetrazol-5-yl)ethylcarbamoyl)cyclopentyl)acetate (39 mg, 0.069 mmol) in MeOH (6 mL) was hydrogenated in H-Cube (Cartridge; 10% Pd/C) at room temperature for 0.5 hour. The reaction mixture was concentrated in vacuo. This was treated with 2M NaOH aqueous solution (1 mL) and MeOH (1 mL) and stirred for 0.5 hour. The reaction mixture was acidified with 1M HCl and the mixture was purified by reverse phase HPLC (column; Sunfire C-18, eluent; 0.1% TFA-H2O/CH3CN) to give {1-[(S)-2-biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylcarbamoyl]-cyclopentyl}-acetic acid (2.5 mg). LCMS (condition C): 420 (M+1); retention time=1.70 min. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.36-1.54 (m, 6H), 1.87-1.98 (m, 2H), 2.59 (s, 3H), 2.59 (s, 2H), 3.22-3.66 (m, 2H), 5.39-5.48 (m, 1H), 7.29-7.37 (m, 3H), 7.44 (t, J=8.08 Hz, 2H), 7.55 (t, J=8.34 Hz, 2H), 7.59-7.64 (m, 2H), 8.17 (d, J=8.08 Hz, 1H); HRMS (ES+) m/z for C23H25N5O3 [M+H]+ calcd 419.2. found 419.2
Workup
- concentrationThe reaction mixture was concentrated in vacuo
- additionThis was treated with 2M NaOH aqueous solution (1 mL) and MeOH (1 mL)
- customthe mixture was purified by reverse phase HPLC (column; Sunfire C-18, eluent; 0.1% TFA-H2O/CH3CN)
Sources & evidence
- ORD record
- ord-f3a0c1e03acd490c96ba66c76d991b70
- Source dataset
- uspto-grants-2014_11
- Patent number
- US08877815B2
Reaction notes
Loading…